Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst/Investor Meet Intimation03-06-2024
03-06-2024
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Management
Resignation of Mr. C.S. Venkatesan, Sr. Vice President (R&D) and Senior Management Personnel of the Company31-05-2024
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Earnings Conference Call held on May 22, 202429-05-2024
Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund & Others29-05-2024
Gland Pharma Ltd - 543245 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the financial year ended March 31, 202428-05-2024
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation regarding schedule of Analyst/Investor Meet on May 28, 202427-05-2024
Gland Pharma Ltd - 543245 - US FDA Inspection At JNPC Facility, Visakhapatnam
US FDA Inspection at JNPC Facility, Visakhapatnam24-05-2024
Gland Pharma Shares Rise The Most In Nine Months As Profit More Than Doubles
Motilal Oswal has cut its earnings estimates by 11%/9% for FY25/FY26, factoring in the extended operational challenges, slower progress in the China business, and a higher effective tax rate.23-05-2024
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper publication of Audited Financial results for the year ended 31.03.202423-05-2024
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earnings Conference Call Recording - Q4FY2422-05-2024